Comments and Contemplations From the 2011 ADA Meeting
Blog Address:
June 26, 2011

Is HbA1C alone the best determinant of Prediabetes?

A study presented by Yoriko Helanza, RD evaluated the use of the HbA1C range (5.7-6.4%) and fasting plasma glucose (100-125 mg/dl) to classify prediabetes in a Japanese population. 20 percent of individuals were classified as having prediabetes without impaired fasting glucose. Screening with  Hgb A1C alone missed 61% of the total number of prediabetic individuals diagnosed with the combination of HbA1C and impaired fasting glucose.

Do you use HbA1C alone to diagnose prediabetes?  If so, maybe that is not enough?

Posted By: Jeffrey Freeman  

June 25, 2011

Look AHEAD Four -Year Data

The Symposium was chaired by Donna Ran MD with  the following excellent speakers: F. Xavier-Sunyer MD, Jessica Unick, PhD, John Jakicic PhD, Alain Bertoni MD, and Samuel Kuna MD.

This study is important for clinicians, because it addresses whether there is a difference in CVD outcome in two groups: Intensive Lifestyle Intervention (ILI) ver...

Posted By: Jeffrey Freeman  

July 11, 2010

Some posters to ponder

There were several posters discussing new agents and classes for the treatment of type 2 diabetes, including some devoted to the SGLT2 class (a selective inhibitor of the renal sodium glucose co-transporter 2). 

A study performed by Parikh et al entitled Dapaglifloxin: An Effective Treatment Option in Patients with Type 2 Diabetes across the Status of Disease evaluat...

Posted By: Jeffrey Freeman  

July 7, 2010

Take-home Points from ACCORD at the ADA

Dr. Henry Ginsberg discussed the effects of combination of lipid therapy (simvastatin and fenofibrate) compared with simvastatin alone to reduce cardiovascular disease in patient's with type 2 diabetes mellitus at high risk for cardiovascular disease.MACE was the primary end point. The primary outcome reached a 2.24 annual rate with the fenofibrate- simvastatin  and a 2.41% annual rate wit...

Posted By: Jeffrey Freeman  

July 5, 2010

More Symposia of Interest

The session entitled Diabetic Dyslipidemia was quite interesting. These are just a few points.

High density lipoprotein cholesterol in diabetes: Is too much of a good thing harmful? Dr. Tina Costacou illustrated information regarding  HDL cholesterol in both genders of less than than 50 placing these individuals  at a higher risk for CVD events.  This loss of ca...

Posted By: Jeffrey Freeman  

June 28, 2010

A Continued Look at New and Upcoming Therapies

Today's presentations began with the symposium entitled Incretin Comparisons.  I must say this was quite interesting with several take-home points.  Several oral presentations focused on the T-emerge trials, which are the regulatory trials for Taspoglutide.  Several combinations with Taspoglutide were discussed.  The T-emerge 4 trial involved Taspoglutide compared with sitag...

Posted By: Jeffrey Freeman  

June 27, 2010

Will TZDs Just Fade Away?

I attended the symposium entitled, "The Clinical Role of TZD's in 2010." The first speaker was Dr. Thomas Buchanan. His topic pertained to the benefits of TZD's on the beta cell. A few take-home points included: predictors of beta cell decompensation were a falling insulin sensitivity, reduced adiponecton levels, and increased CRP.

Both the TRIPOD and PIPOD studies s...

Posted By: Jeffrey Freeman  

June 25, 2010

The Night Before

I always look forward to the ADA scientific meetings, which I usually attend each year for about 20 years.  It is quite challenging to organize your days events so that you maximize your time efficiency.  This years meeting is quite comprehensive with several areas of specific interest.  To name a few: more information on existing GLP-1 receptor analogues and others in developmen...

Posted By: Jeffrey Freeman  

About This Blog

The American Diabetes Association is holding its annual meeting June 24-28 in San Diego, California. This blog provides highlights from some of the sessions and invites you to discuss the findings with your colleagues.

Disclosure: Jeffrey S. Freeman, DO, FACOI, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers’ bureau for: Merck, Novo Nordisk, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline, Amylin Pharmaceuticals, Inc.


All material on this website is protected by copyright, Copyright © 1994-2014 by WebMD LLC. This website also contains material copyrighted by 3rd parties.